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Glucagon, a key hormone in the regulation of glucose homeostasis, acts as a
counter-regulatory hormone to insulin by promoting hepatic glucose output. Under normal
conditions, insulin and glucagon operate in concert to maintain the glucose level within
a narrow physiological range. In diabetes, however, while insulin secretion or action is
insufficient, the production and secretion of glucagon are excessive, contributing to the
development of diabetic hyperglycemia. Within an islet, intra-islet insulin, in cooperation
with intra-islet GABA, suppresses glucagon secretion via direct modulation of α-cell
intracellular signaling pathways involving Akt activation, GABA receptor phosphorylation
and the receptor plasma membrane translocation, while intra-islet glucagon plays an
important role in modulating β-cell function and insulin secretion. Defects in the
insulin-glucagon fine-tuning machinery may result in β-cell glucose incompetence, leading
to unsuppressed glucagon secretion and subsequent hyperglycemia, which often occur
under extreme conditions of glucose influx or efflux. Therefore, deciphering the precise
molecular mechanisms underlying glucagon secretion and action will facilitate our
understanding of glucagon physiology, in particular, its role in regulating islet β-cell
function, and hence the mechanisms behind glucose homeostasis.
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BACKGROUND
Glucagon is a 29-amino acid peptide synthesized and released
from the pancreatic α-cells, where it is produced through the
cleavage of proglucagon by prohormone convertase 2 (Rouille
et al., 1997; Jiang and Zhang, 2003). Glucagon exerts its biolog-
ical actions through the activation of glucagon receptors (Gcgr),
which is a G protein-coupled receptor found in various parts of
the body including the liver, kidney, adipose tissue, brain, and the
pancreatic β-cells (Burcelin et al., 1995). Activation of glucagon
receptor, particularly in the liver, is a critical determinant in con-
trolling the rate of gluconeogenesis and glycogenolysis (Unger,
1985; Lefebvre, 1995). The production and secretion of glucagon,
which enhance hepatic glucose production, are important mech-
anisms by which the body prevents hypoglycemia (Unger, 1985;
Lefebvre, 1995). In both animals (Myers et al., 1991; Young
et al., 1993) and humans (Lins et al., 1983; Freychet et al., 1988;
Hvidberg et al., 1994), the administration of exogenous glucagon
elevates glucose levels during a fasted or fed state. Therefore,
glucagon is an effective therapy for treating severe hypoglycemia
in humans (Freychet et al., 1988; Carstens and Andersen, 1994;
Haymond and Schreiner, 2001; Kedia, 2011).
Postprandial hyperglycemia stimulates insulin secretion,
which acts on the liver to suppress glucose production.
Concomitantly, increased blood glucose levels suppress glucagon
secretion and reduce its stimulatory effects on hepatic glucose
production. During insulin-induced hypoglycemia, glucagon
raises blood glucose levels by enhancing glycogenolysis and
gluconeogenesis (Bansal and Wang, 2008) to restore nor-
moglycemia (Freychet et al., 1988). The maintenance of
normoglycemia relies on the body’s response to a change in the
insulin-to-glucagon ratio. During a fed state, an increase in the
ratio promotes the transport of excess glucose from the blood to
tissues in order to prevent postprandial hyperglycemia (Jiang and
Zhang, 2003). During a fasted state, a decrease in glucose lev-
els stimulates hepatic glucose output, preventing hypoglycemia
(Unger, 1985).
Excessive secretion of glucagon contributes to the develop-
ment of diabetic hyperglycemia as a consequence of increased
hepatic glucose production (Sherwin et al., 1976; Unger, 1978;
Barg et al., 2000; Gastaldelli et al., 2000). Preclinical studies
demonstrated that chronic glucagon perfusion resulted in hyper-
glycemia, glomerular abnormalities, and impaired glucose toler-
ance, which are symptoms of early stage type 2 diabetes (Li et al.,
2008). Interestingly, acute infusion of glucagon resulted in sus-
tained hyperglycemia as a consequence of stimulated gluconeoge-
nesis and glycogenolysis in the liver (Gastaldelli et al., 2000; Shah
et al., 2000), which, however, occurred only in human diabetic
subjects with impaired β-cell function, but not in non-diabetic
subjects (Rizza et al., 1979). Interestingly, in insulin-withdrawn
diabetic patients, the glycemic response to hyperglucagonemia
is much greater than those in non-diabetic controls (Sherwin
et al., 1976), suggesting that in diabetic individuals, abnormal-
ities in the secretion of not only glucagon, but also insulin,
along with the alteration of the glucagon-to-insulin ratio, lead
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to hyperglucagonemia (Bansal and Wang, 2008; Unger and Orci,
2010).
Since insulin is a physiological suppressor of glucagon
secretion (Bansal and Wang, 2008), relative insufficient insulin
production or declined insulin action in type 2 diabetes may
reduce intra-islet insulin action on the suppression of glucagon
secretion from the α-cells (Greenbaum et al., 1991). At the cellular
and molecular levels, we have demonstrated that chronic expo-
sure of α-cells to high concentrations of glucose and insulinmight
impose insulin resistance on these cells (Xu et al., 2006). Insulin
resistance in α-cells may result in concurrently unsuppressed
glucagon secretion under insulin-stimulatory conditions (Bansal
andWang, 2008; Yan et al., 2009). Thus, in type 2 diabetes, despite
the β-cells working at maximum capacity to produce and secrete
insulin, hyperglucagonemia, and hyperglycemia persist due to
insulin resistance in the α-cells (Xu et al., 2006).
Hypoglycemia can produce a variety of detrimental complica-
tions, and sometimes with fatal outcomes. This is a considerable
challenge in insulin therapy as failure of glucagon counterreg-
ulation during hypoglycemia is a key factor limiting insulin
treatment in patients with diabetes (Bolli, 1998; Cryer et al.,
2003). Since the brain relies on glucose as its sole source of
energy, profound hypoglycemia can cause permanent neurolog-
ical damage, leading to functional brain failure, and even brain
death (Cryer, 2007). It should be noted that, during exogenous
insulin therapy, insulin levels do not decrease when glucose lev-
els fall. Persistent suppression of α-cell response may result in
defective glucose counterregulation, leading to insulin-induced
hypoglycemia, as a consequence of lacking hepatic glucose pro-
duction under glucagon-stimulated conditions. Iatrogenic hypo-
glycemia is usually associated with recurrent morbidity in most
patients with type 1 diabetes and many with type 2 diabetes
(Bolli, 1998; Cryer et al., 2003). Mechanistically, during insulin
therapy for type 1 diabetes, the exogenous level of insulin does
not decrease in response to the lowering of blood glucose, due
to a lack of endogenous glucose-sensing mechanisms (Stutzer
et al., 2012). In type 2 diabetes, however, chronic intra-islet
hyperinsulinemia may cause α-cell resistance (Tsuchiyama et al.,
2007). Presumably, under insulin-stimulatory conditions, intra-
islet insulin action may not be able to efficiently exert suppressive
effects on α-cell secretion, whereas under glucagon-stimulatory
conditions, intra-islet hyperinsulinemia prevents the glucagon
response to hypoglycemia (Banarer et al., 2002). Therefore, per-
sistent suppression of glucagon secretion by exogenous insulin
impairs the insulin-glucagon fine-tuning system that predomi-
nantly maintains glucose homeostasis, and may result in iatro-
genic hypoglycemia (Bolli, 1998; Cryer et al., 2003). Particularly,
in type 1 diabetes, the lack of insulin-secreting β-cells diminishes
the suppressive effect of endogenous insulin on α-cell secretion.
As a consequence, the α-cells may become more sensitive to
exogenous insulin (Bansal and Wang, 2008).
MECHANISMS OF GLUCAGON SECRETION
Glucose is a predominant factor limiting glucagon secretion
(Gerich et al., 1974; Maruyama et al., 1984; Matsuda et al.,
2002). The insulin-producing β-cells and the glucagon-secreting
α-cells are each featured with a unique set of ion channels
(Kanno et al., 2002; Leung et al., 2005) and are both electrically
excitable. The two types of islet cells work in a coordinated man-
ner such that an “on-off” mechanism is established to fine-tune
the secretion of insulin and glucagon, and insulin-glucagon levels.
Typically, under insulin-stimulatory glucose concentrations, β-
cells are electrically excitatory, and the α-cells are electrically silent
(Gopel et al., 2000). Within the islets, the regulation of glucagon
secretion by glucose and paracrine factors (i.e., the β-cell secre-
tory products) is mediated by electrical machinery comprising
of a variety of ion channels that determine depolarization or
hyperpolarization of the α-cells (Gopel et al., 2000; Cejvan et al.,
2003; Gromada and Rorsman, 2004; Gromada et al., 2004; Yan
et al., 2009). The secretion of glucagon requires a full depolar-
ization cascade involving the sequential activation of a number
of ion channels. Particularly, the activation of T-type Ca2+ chan-
nels depolarizes the cell to an intermediate membrane potential
which activates the tetrodotoxin (TTX)-sensitive Na+ channels;
the influx of Na+ ions further depolarizes the α-cell, leading
to the activation of the L- or N-type Ca2+ channels and the
generation of sustained Ca2+ influx, triggering glucagon gran-
ule exocytosis. The hyperpolarization-activated cyclic nucleotide-
gated (HCN) channels, expressed in the α-cells, are presumably
involved in initiating the depolarization cascades (Zhang et al.,
2008). Maintenance of the ATP-sensitive K+ (KATP) channel
activity in α-cells within an appropriate range is critical for allow-
ing the operation of this machinery (Bansal and Wang, 2008). At
high glucose concentrations, the closure of the KATP channels, as
a consequence of increased intracellular ATP/ADP ratio, depolar-
izes the α-cell membrane potential beyond the narrow window,
causing voltage inactivation of the depolarization cascade (Bansal
and Wang, 2008). At low glucose concentrations, however, the
opening of KATP channels only occurs in a subpopulation of
these channels on the α-cell and sets the membrane potential to
a very negative value, causing the activation of the T-type Ca2+
channels and/or the HCN channels to trigger the subsequent
depolarization cascades (Gopel et al., 2000; MacDonald et al.,
2007). Importantly, under insulin-stimulatory conditions, insulin
appears to be predominant in suppressing glucagon secretion,
presumably through either direct interference of the KATP channel
activity, or the α-cell membrane potential—which is exempli-
fied by the insulin-induced activation of the type A receptor
for γ-Aminobutyric acid (GABAAR)—causing membrane hyper-
polarization, or the suppression of the glucagon gene (Bansal
and Wang, 2008). Insulin, in cooperation with GABA, suppresses
glucagon secretion via direct phosphorylation of GABAAR by
protein kinase B (or Akt), a key molecule in insulin signaling that
leads to the translocation of the receptors from intracellular pools
to the cell surface and the subsequent membrane hyperpolariza-
tion and closure of voltage-dependent calcium channels (Xu et al.,
2006).
Intra-islet insulin action has a predominant role in the reg-
ulation of glucagon secretion from the α-cells. Previous studies
suggested that insulin signaling in the α-cells plays an important
role in glucose-dependent glucagon secretion. In clonal glucagon-
secreting α-cell lines, the ablation of the insulin receptor using
siRNA techniques diminished high-glucose-induced suppression
of glucagon secretion (Diao et al., 2005). Furthermore, mice
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lacking α-cell specific insulin receptor exhibited elevated glucagon
secretion, hyperglucagonemia in the fed state, impaired glucose
intolerance and hyperglycemia (Kawamori et al., 2009), indi-
cating the inhibitory effects of intra-islet insulin on glucagon
secretion (Bansal and Wang, 2008). The concept that insulin is a
physiological suppressor of glucagon secretion is also supported
by clinical studies. Studies involving clamp technique, which
keeps glucose constant and thus allows for the effects of changes in
glucose levels on glucagon secretion to be readily isolated, showed
that administrations of insulin suppressed glucagon secretion in
healthy humans (Raskin et al., 1975), and patients with type 1
(Raskin et al., 1976) or type 2 diabetes (Greenbaum et al., 1991;
Hamaguchi et al., 1991). Similar observations were obtained in
diabetic animal models (Braaten et al., 1974; Blazquez et al.,
1976). Conversely, blockage of insulin signaling using insulin neu-
tralizing antibody significantly increased glucagon levels in the
perfused pancreas of rodents (Maruyama et al., 1984). At the
molecular level, insulin can activate intra-islet insulin signaling
involving the activation of the PI3K/Akt signaling pathway, which
induces subsequent phosphorylation of the β subunit of GABAAR
and the translocation of receptors from the intra-cellular pool
to the plasma membrane. The resulting increase in the α-cell
surface expression of GABAARs leads to α-cell membrane hyper-
polarization and the suppression of glucagon secretion (Xu et al.,
2006).
The unique arrangement of islet microvasculature is closely
associated with the regulatory role of insulin on glucagon release.
It has been previously demonstrated in both human and ani-
mal models that α-cells are located downstream of β-cells
(Bonner-Weir and Orci, 1982; Stagner et al., 1988; Stagner and
Samols, 1992). This permits a direct regulation of glucagon
secretion by exposing α-cells to a high concentration of insulin.
A recent study suggested that the cytoarchitecture of pancre-
atic islets may differ among species (Cabrera et al., 2006).
Although human islets are morphologically different from those
of rodent islets, such that the β-cells are located in the core
and α-cells in the mantle, the human islets displayed anatom-
ical subdivisions in which the β-cells are surrounded by α-cells
(Cabrera et al., 2006; Bosco et al., 2010).
Insulin also inhibits glucagon synthesis by means of repressing
the proglucagon gene (Chen et al., 1989; Philippe, 1989), presum-
ably through the activation of the PI3K/Akt signaling pathway
(Schinner et al., 2005). Several co-factors and transcription fac-
tors, including FoxO1 and Foxa2, are critical in mediating this
transcriptional regulation through their direct binding to the
proximal promoter region of the proglucagon gene (Philippe
et al., 1995; Gauthier et al., 2002; Schinner et al., 2005; McKinnon
et al., 2006). The evidence that the ablation of this in trans
process diminishes the inhibitory effects of insulin on glucagon
biosynthesis and secretion (McKinnon et al., 2006) illustrates the
importance of intra-islet insulin in modulating α-cell function.
Insulin is not the sole regulator within an islet: glucagon
secretion is regulated in autocrine and paracrine fashions, involv-
ing a number of islet cell secretory products including GABA
produced by the β-cells (Xu et al., 2006; Braun et al., 2010), glu-
tamate produced by the α-cells (Eto et al., 2003; Salehi et al.,
2004; Uehara et al., 2004; Cabrera et al., 2006), somatostatin
(Cejvan et al., 2003; Hauge-Evans et al., 2009), and possibly
incretins (Gromada and Rorsman, 2004; Marchetti et al., 2012)
and ghrelin (Salehi et al., 2004; Zhou et al., 2007). It should
be noted that L-glutamate and GLP-1 are known to stimu-
late insulin secretion; thus, their inhibitory effects on glucagon
may be indirect and mediated through insulin actions. Clinical
evidence suggests that indirect reciprocal β-cell–mediated sig-
naling of α-cells appears to be predominant over the direct
α-cell signaling in the regulation of glucagon secretion (Banarer
et al., 2002; Gosmanov et al., 2005). This notion is consis-
tent with the physiological relevance underlying glucagon secre-
tion. For instance, under euglycemic basal conditions, β-cell
secretory products tonically restrain α-cell glucagon secretion;
under β-cell stimulatory conditions, i.e., after meal ingestion, an
increase in β-cell secretion counteracts the direct α-cell stimula-
tion, leading to no change or suppression of glucagon secretion
from the α-cells (Cooperberg and Cryer, 2009). However, in
hypoglycemia, a decrease in β-cell secretion, in concert with
a low α-cell glucose concentration, stimulates α-cell glucagon
secretion (Barg et al., 2000; Bevan, 2001; Banarer et al., 2002;
Bancila et al., 2005). This regulatory mechanism is further sup-
ported by a recent study indicating that an increase in insulin
per se suppresses glucagon secretion and a decrease in insulin
per se, in concert with a low glucose concentration, stimu-
lates glucagon secretion in humans (Cooperberg and Cryer,
2010).
Interestingly, insulin coordinates with GABA to suppress α-cell
secretion via α-cell membrane hyperpolarization, which inhibits
the exocytotic machinery (Xu et al., 2006). In contrast, when
this cooperation occurs in β-cells, it enhances β-cell secretion in
a fine-tuned range (Bansal et al., 2011). GABA, a non-coding
amino acid produced by β-cells, induces membrane hyperpo-
larization of α-cells (Xu et al., 2006), whereas in the β-cells, it
exerts depolarizing trophic effects (Soltani et al., 2011; Braun
et al., 2010). Furthermore, the glutamate released from the α-cells
can act upon its own cells, although controversial (Uehara et al.,
2004), to potentiate (Cabrera et al., 2008) its own secretory ability
in an autocrine fashion.
Activation of α-cell insulin receptor stimulates GABAAR phos-
phorylation at the β3 subunit, enhancing cell surface expression
of the GABAAR and leading to α-cell hyperpolarization and
subsequent suppression of glucagon secretion (Xu et al., 2006;
Bansal and Wang, 2008) (Figure 1). In cultured clonal α-cells,
GABAAR insertion into the plasma membrane is mediated by
insulin signaling involving the activation of the PI3K/Akt sig-
naling pathway. In isolated rat islets, treatment with glucose
suppressed glucagon secretion, as a result of enhanced intra-
islet insulin action on the α-cells; insulin signaling blockage
in α-cells diminishes glucose-induced suppression of glucagon
secretion (Xu et al., 2006). Therefore, the intra-islet insulin-
Akt- GABAAR pathway is critical in the regulation of glucagon
secretion and maintaining an appropriate insulin-to-glucagon
ratio (Xu et al., 2006), which is essential for keeping the blood
glucagon within a normal range. Remarkably, in a cellular
model of “insulin resistance,” where high concentrations of glu-
cose and insulin are exposed to α-cells to mimic hyperglycemia
and hyperinsulinemia, subsequent applications of insulin fail
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FIGURE 1 | A model shows mechanisms underlying intra-islet hormonal
regulation and their impact on liver glucose production. (1) Insulin,
incorporation with GABA produced from β-cells suppresses glucagon
secretion via membrane hyperpolarization. (2) Glucagon stimulates
glucose-competent β-cell secretion and increases α-cell gene transcription via
activation of CREB. (3) Glucagon increases its action in the liver on glucose
production under glucagon stimulatory conditions. (4) Insulin increases the
suppressive effect of insulin on hepatic glucose production by reducing
gluconeogenesis and glycogenolysis. Insulin suppresses glucagon secretion
via modulating KATP channels and repressing the proglucagon gene, as well
as the effects of glucagon and insulin on a variety of organs and tissues are
not shown.
to increase GABAAR on the cell surface and fail to inhibit
glucagon secretion (Xu et al., 2006). These findings provide a
molecular mechanism by which glucose-induced suppression of
glucagon secretion is mediated by the intra-islet insulin-Akt-
GABAAR pathway (Figure 1). Defects in this signaling pathway,
referred to as α-cell insulin resistance (Larsson and Ahren, 2000;
Xu et al., 2006), appear to be a major contributor to hyper-
glucagonemia and hyperglycemia in type 2 diabetes. Evidence
supporting this notion is consistent with clinical observations
that α-cell insulin resistance exaggerates glucagon responses to
stimuli in type 2 diabetic patients (Tsuchiyama et al., 2007).
This pathway may also provide a mechanistic explanation, at
least in part, for hypoglycemia occurring in insulin-treated
type 1 diabetic patients. The α-cells of these patients, due
to a lack of suppression by endogenous insulin, were ren-
dered hypersensitive to exogenous insulin (Bansal and Wang,
2008).
MECHANISMS OF GLUCAGON ACTION
The mechanism underlying the regulation of α-cell mass
expansion and glucagon in response to metabolic changes has
not been extensively studied. Observations from a recent study
using db/db mice demonstrated that α-cell mass increased dur-
ing the development of insulin resistance and hyperinsulinemia
(Liu et al., 2011). The expansion of α-cell mass under insulin
resistant conditions is likely a direct adaptive response to com-
pensate increased demand for insulin in these diabetic mice.
This is consistent with the observations that lacking α-cell mass
expansion and glucagon secretion may cause secondary inabil-
ity of the β-cell mass to adapt peripheral insulin resistance in
mice under excessive nutrient feeding conditions (Ellingsgaard
et al., 2008). Thus it is suggestive that, the intra-islet glucagon
plays an important role in the maintenance of β-cell mass home-
ostasis and β-cell competence. This notion is consistent with the
findings that treatment of glucagon potentiates glucose-induced
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insulin release in isolated adult human islets (Huypens et al.,
2000). The perception is further supported by the evidence that
transgenic murine pancreatic β-cells specifically overexpressing
GCGR displayed enhanced glucose-competent insulin secretion,
associated with increased β-cell mass and pancreatic insulin
content, rendering the mice partially protected from high-fat
diet feeding-induced hyperglycemia and impaired glucose tol-
erance (Gelling et al., 2009). Conversely, impaired β-cell func-
tion exemplified by declined glucose-induced insulin in isolated
islets were profound in Gcgr−/− mice lacking glucagon actions
(Sorensen et al., 2006). Furthermore, pancreas perfusion stud-
ies using specific GCGR antagonists suggested that the intra-
islet glucagon-induced trophic effects on the β-cells are mainly
through GCGR rather than GLP-1 receptors on islet β-cells
(Kawai et al., 1995), although the gut-derived insulinotropic hor-
mone is recently found to be also produced by the α-cells and
exerts local actions (Marchetti et al., 2012). The intra-islet trophic
effects of glucagon have been further studied using transgenic
mice expressing GCGR under control of the muscle specific crea-
tine kinase (Mck) promoter (Maharaj et al., 2012). The Mck/Gcgr
mice, which displayed mild hyperglucagonemia (but unchanged
circulating GLP-1 levels), are euglycemic under basal conditions
but are resistant to streptozotocin-induced β-cell injury partially
due to enhanced intra-islet action of both glucagon and insulin
on β-cell competence (Maharaj et al., 2012).
ROLE OF GLUCAGON IN DIABETES
Chronic hyperglucagonemia is a major contributor to the devel-
opment of diabetic hyperglycemia, due to excessive hepatic glu-
cose output either under basal or postprandial conditions (Jiang
and Zhang, 2003). Therefore, a strategy involving neutralizing
peripheral glucagon actions may be beneficial for hyperglycemia
in diabetes. This notion has been tested in recent studies using
antibodies antagonizing GCGR, and it has been shown that
administration of monoclonal antibodies normalized blood glu-
cose levels in obese diabetic mice and improved glucose toler-
ance in normal mice and monkeys (Gu et al., 2009; Yan et al.,
2009). Various approaches have been reported that are effective in
attenuating glucagon actions, including the use of GCGR antag-
onists and GCGR antisense oligonucleotides (ASOs). Clinical
studies showed that GCGR antagonism significantly reduced
hyperglucagonemic stimuli-induced hyperglycemia in humans
(Petersen and Sullivan, 2001). Consistently, reduction in GCGR
expression using ASOs significantly decreased blood glucose,
circulating triglyceride, free fatty acids, and improved glucose tol-
erance by diminishing glucagon actions in type 2 diabetes prone
db/dbmice (Liang et al., 2004). The effects of ablation of glucagon
actions on the development of insulin-deficient diabetes have
been studied in glucagon receptor knockout mice (Gcgr−/−).
Despite hyperglucagonemia, as a consequence of pancreatic α-cell
hyperplasia and excessive glucagon production, Gcgr−/− mice
are hypoglycemic (Gelling et al., 2003). Interestingly, ablation
of the β-cells using high-dose streptozotocin, though causing
severe hyperglycemia and hyperketonemia in the wildtype litter-
mates, did not cause hyperglycemia or laboratory manifestations
of diabetes in these knockout mice, indicating that ablating Gcgr
prevents insulin-deficient type 1 diabetes in mice (Lee et al.,
2011). The critical role of glucagon in the maintenance of glu-
cose homeostasis had been further illustrated in the Gcgr−/−
mice when adenoviral restoration of hepatic GCGR expression
consented to the occurrence of diabetes in these mice after strep-
tozotocin destroyed their β-cells (Lee et al., 2012), suggesting
that hepatic glucagon suppression is a key therapeutic target in
diabetes.
Glucagon plays a pivotal role in maintaining functions of var-
ious organs and tissues. Although ablation of hepatic glucagon
actions can prevent the occurrence of diabetic hyperglycemia
and metabolic manifestations following β-cell destruction (Lee
et al., 2011, 2012), complete elimination of glucagon action
can produce adverse effects, which are exemplified by the phe-
notypes of Gcgr−/− mice who have increased fetal lethality,
defective islet development and impaired glucose competence
in the β-cells (Sorensen et al., 2006; Vuguin et al., 2006). To
investigate the effects of attenuating hepatic glucagon actions
while enhancing intra-islet glucagon actions, our laboratory
has generated Mck/Gcgr mice, a line with muscle-specifically
expressing GCGR (Maharaj et al., 2012). The rationale behind
this approach is that the ectopic overexpression of GCGR in
the skeletal muscle, where little GCGRs are produced endoge-
nously, creates a decoy receptor to neutralize excess circulating
glucagon and elevates intra-islet glucagon action as a conse-
quence of α-cell compensation to the trapping of glucagon in the
muscle in Mck/Gcgr mice (Maharaj et al., 2012). These trans-
genic mice displayed a significant decrease in hepatic glucose-
6-phosphatase and fructose-1,6-bisphosphatase mRNA levels,
suggesting a reduction in gluconeogenesis and glycogenolysis.
Remarkably, the Mck/Gcgr mice are euglycemic and possess
higher capability in maintaining glycemic stability, particularly
under extreme conditions of glucose influx or efflux exempli-
fied by β-cell injury (Maharaj et al., 2012) and excessive nutrients
feeding (Maharaj andWang unpublished data). The reduced liver
gluconeogenesis, glycogenolysis and elevated intra-islet glucagon
action as a consequence of glucagon trapping and α-cell compen-
sation, respectively, suggest that neutralizing peripheral glucagon
actions, while enhancing intra-islet glucagon actions, may present
a useful therapeutic approach for diabetes.
SUMMARY
Glucose is a primary determinant of glucagon secretion by α-
cells. Within an islet, glucose-stimulated insulin secretion acts as
a potent primary physiological regulator to suppress glucagon
secretion through a mechanism involving the activation of the
insulin-GABA signaling pathway, modulation of KATP activity
and suppression of proglucagon gene expression. The regulation
of glucagon secretion is multifaceted, and the process of reg-
ulating glucagon secretion involves other factors including the
autonomic nervous system, somatostatin, ion channels, GLP-1
and L-glutamate. It should be noted that L-glutamate and GLP-1
are known to stimulate insulin secretion; thus, their inhibitory
effects on glucagon may be indirect and mediated through
insulin actions. Glucagon plays a pivotal role in protecting the
body against hypoglycemia through enhanced hepatic output by
stimulating glycogenolysis and gluconeogenesis while inhibiting
glycolysis and glycogenesis. Intra-islet paracrine glucagon action
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on modulation of β-cell function is important in the mainte-
nance of β-cell glucose competence, particularly under extreme
conditions of glucose influx and efflux. Therefore, an approach
that suppresses liver glucose production while enhancing intra-
islet glucagon actions may present a new therapeutic strategy for
diabetes.
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